Executive Leadership

Zhiyong Yang PhD, Co-founder and CEO of Fzata, Inc. Dr. Yang received her PhD degree from U. of Arizona and received postdoc training at Massachusetts General Hospital. Dr. Yang is an expert on characterizing therapeutic antibodies against CDI with 10 peer-reviewed papers on C. diff. subject matter. Dr. Yang is one of the inventors on the Fzata patent applications. Prior to Fzata, Dr. Yang worked in industry for six years on various preclinical and clinical stage drugs. Under Dr. Yang's leadership , Fzata won “2017 Maryland Incubator Company of the Year, Best Life Sciences Company”, and NOVA’s 2022 Mid-Atlantic Innovation winner for biotechnology. Dr. Yang was awarded the Greater Baltimore Committee (GBC) Bridging the Gap Achievement Award 2022

for exceptional majority, minority and women-owned businesses and executives.

Dr. Yang’s leadership has achieved NIH non-dilutive funding totaling of over $24MM for Fzata.

Hanping Feng PhD, Co-Founder & Chief Scientific Officer of Fzata. Dr. Feng received his PhD degree from U. of Arizona and received postdoc training at Harvard Medical School and is a full Professor and Vice Chair of Department of Microbial Pathogenesis at the University of Maryland School of Dentistry. Dr. Feng is an internationally renowned expert in C. difficile host immune response and pathogenesis and is the leading inventor on key technology patents covering full-length active recombinant C. difficile TcdA and TcdB, antibodies against C. difficile toxins as well as all associated BioPYM technologies. He has established several CDI animal models, and generated a novel chimeric toxin vaccine and multi-specific antitoxin antibodies.
Dr. Feng’s lab has been funded by NIH as well as leading pharmaceutical companies including Pfizer and Merck.

Elizabeth Smith PhD, MBA, Chief Business Officer at Fzata. Dr. Smith’s career is centered on driving scientific innovations to patients. She creates effective teamwork among scientists, entrepreneurs, and legal teams, increasing enterprise value. With her assistance, dozens of biopharma companies have raised over $50 MM non-dilutive funding plus many licensing and other partnership deals. Dr. Smith first engaged with Fzata, Inc. in 2016 as a consultant. In 2022, inspired by the world-changing potential of the BioPYM platform, she joined full time as Chief Business Officer to lead fund raising and partnering efforts. She works closely with the CEO to define and execute corporate vision and strategy. Dr. Smith earned a PhD in Biochemistry and Molecular Biology from the University of Chicago (1999). An interest in expediting the transition of scientific discoveries to patients led her to a position as project manager at the University of Chicago Technology Transfer Office -redirecting her career to early stage pharma strategic business development and licensing. Dr. Smith earned an MBA from University of Chicago Booth School of Business (2006).

Advisors

Clinical Advisors- C. diff. Infection

Dr. Ciaran Kelly, Professor at Harvard Medical School, Chief of the Herrman L. Blumgart Internal Medicine Firm, Director of the Celiac Center at Beth Israel Deaconess Medical Center. Dr. Kelly earned his MD degree from Trinity College in Dublin and is the author of more than 150 clinical and basic research book chapters, invited reviews, and peer-reviewed publications. Dr. Kelly is a world-renowned expert in C. diff. basic and clinical research, and has led several clinical trials, including the trials of Merck’s antibody for CDI and a recently completed clinical trial studying the effects of S. boulardii on gut microbiota.

Dr. Wilbur Chen, Professor of Medicine at University of Maryland. He is an adult infectious disease physician-scientist. He develops and conducts human experimental challenge studies to gain new insights into pathogenesis, the immune response, or early efficacy of candidate vaccines or therapeutics. Dr. Chen serves as voting member of the CDC’s Advisory Committee on Immunization Practices and core member of NIAID's Data and Safety Advisory Board.

Dr. Erik von Rosenvinge, Associate Professor U. MD and Chief of Gastroenterology, VA Maryland Health Care System. Dr. von Rosenvinge's research and clinical interests include C. difficile infection, the gastrointestinal microbiome, fecal microbiota transplantation, and improving colorectal cancer screening.

Clinical Advisors- Inflammatory Bowel Disease (IBD)

Dr. Bruce Sands, Mount Sinai NY Chief of Gastroenterology since 2010. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital's Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School. Dr. Sands has completed over two dozen ulcerative colitis clinical trials.

Dr. Adam Cheifetz, Director of the Center for Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is Director of the Harvard Medical School Gastroenterology Clerkship Elective and Assistant Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center. Dr Cheifetz specializes in the treatment of Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases.

Dr. Huimin Yu, is Assistant Professor of Medicine Johns Hopkins Medicine. Active in her research, Dr. Yu’s clinical interests include the diagnosis and management of inflammatory bowel disease (IBD) and chronic diarrhea disease. She is committed to a career as a physician-scientist with focus on host-pathogen interactions and inflammatory bowel disease (IBD). Dr. Yu’s goal is to translate her research into better patient care especially for those who suffer from diarrhea and IBD.

Nonclinical Advisor

Dr. Rakesh Dixit, the CEO and President of Bionavigen, a company dedicated to developing, consulting and advising the development of highly innovative biotherapeutics. Dr. Dixit has more than 30 years of R&D biopharmaceutical experience with Merck, Johnson and Johnson, and AstraZeneca. He not only was a key player in the development of MEDI3902, a bivalent, bi-specific human immunoglobulin G1κ monoclonal antibody for the prevention of nosocomial P. aeruginosa pneumonia, but also has been a Global Vice President, R&D with AstraZeneca-Medimmune for 13 years.

Business Advisors

Gianna Arnold, Equity partner and vice chair of Saul Ewing Arnstein & Lehr LLP, and CEO of NuMoon Technologies, LLC. Gianna is a corporate and transactional attorney with deep expertise in negotiating strategic alliances and preparing the resulting agreements as well as due diligence analysis in connection with mergers, acquisitions, licensing, and investments including the biopharma vertical. Gianna is also CEO of NuMoon Technologies, LLC, a women-owned small business developing hazard detection tools for the Department of Defense. With her unique experience as a lawyer, chemist, entrepreneur, and corporate executive, she gives highly insightful and strategic advice to enhance Fzata company value.

Arthur H. Bertelsen, Ph.D. Principal Biotech DDBD, LLC. Dr. Bertelsen has extensive experience as a biotech and pharmaceutical executive. He was Vice President at Bristol-Myers Squibb with overall responsibility for global external drug discovery, technology and early development alliances. These external collaborations delivered about one third of the BMS early pipeline during his 10 year tenure. Previous to this he held a similar role at Schering-Plough for 12 years.

Jeff Strovel, Ph.D. Dr. Strovel earned his PhD in Human Genetics from UMB School of Medicine. He is currently Chief Executive Officer for Irazu Oncology with 15 years of executive and leadership experience. He has orchestrated the progression of 4 therapeutic drug candidates from conceptualization to clinical development over his 25 years in the biopharma industry. He has successfully raised over $50MM in venture capital in a syndicate comprised of Sanofi Ventures, Hatteras Venture Fund, Pappas Capital, and the JDRF T1D Fund and closed partnering deals with Sanofi and NIH. He has deep expertise in strategy, leadership, capital raises and deal structure, as well as extensive relationships in the local Maryland bio-pharma ecosystem.

Board of Directors

Dr. Zhiyong Yang, Fzata Founder and CEO

Dr. Hanping Feng, Fzata Founder and CSO

Independent Board Member Seats are open positions